| Print |  Email

AmSurg Shares Rise in Value After $2.35B Sheridan Deal Announcement

Written by Carrie Pallardy | June 10, 2014

Raymond James analyst John Ransom set AmSurg’s price target at $60 and upgraded his recommendation to “buy,” according to a Value Walk report.

The upgrade was made closely following AmSurg’s announcement of intention to acquire Sheridan Healthcare for $2.35 billion.

More Articles on Transactions and Valuation Issues:
4 Recent ASC Industry Acquisitions
Beloit Health System ASC Project Remains in Limbo
3 Recently Opened & Expanded Ambulatory Surgery Centers

© Copyright ASC COMMUNICATIONS 2012. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.